- Poster presentation
- Open Access
Interleukin (IL)- 6 inhibition - Follow-up data of the German AID-registry1
© Bielak et al. 2015
- Published: 28 September 2015
- Proinflammatory Cytokine
- Innate Immune System
- Unknown Etiology
Systemic juvenile idiopathic arthritis (SJIA) is regarded as an autoinflammatory disease (AID) of unknown etiology related to abnormalities of the innate immune system. A major role in the pathogenesis has been ascribed to proinflammatory cytokines as interleukin (IL)-6 and IL-1.
Analysis of treatment results with the IL-6 inhibitor tocilizumab
From 7/2009 to 4/2014 200 patients with SJIA were documented in the AID-registry. 46 of 200 patients (19 m, 27 f) at the age of 1-18 years (median 9) received therapy with tocilizumab (median 13 months, range 1-48). 24 of 46 patients received long term treatment (median 23 months, range 12-48) and were evaluated concerning Wallace criteria . Different clinical courses were continuous (C) n=12, polycyclic (PC) n=16, arthritic (A) n=18. Besides we estimated a response rate (definition: no clinical manifestation and no inflammation parameters) in the first 12 weeks of treatment. Data are based on the AID-Registry (http://www.aid-register.de).
According to Kaplan-Meier analysis 30% reached inactive disease or remission after the first 12 weeks of treatment. A rapid response to tocilizumab seems to be related to long term inactivity of SJIA. Comparison of the three disease courses (PC, C, A) revealed significant differences in the outcome; polycyclic courses show the fastest response followed by continuous courses. Worst outcome was evaluated in arthritic courses. Wallace criteria measured after at least 12 months: remission 54%, active disease 25%, inactive disease 21%. 4 (9%) patients were non-responders over the whole time. 60% of the patients showed no measurable CRP within the first 4 weeks and during tocilizumab therapy. Adverse events were reported in 11 (24%) patients: most leukopenia, infections and elevated transaminases, one Hodgkin's lymphoma, one gut perforation.
A significant proportion of patients documented with SJIA in der German AID-registry is treated with tocilizumab (23%). We estimated a good response in the first 12 weeks of therapy of 30% and also by Wallace of 76% (inactive disease or remission). The response appears to depend on different disease phenotypes.
1The AID-Registry is funded by the BMBF (01GM08104, 01GM1112D)
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.